Compare APT & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APT | ABVC |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.4M | 50.5M |
| IPO Year | 1997 | 2009 |
| Metric | APT | ABVC |
|---|---|---|
| Price | $5.17 | $1.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.2K | ★ 57.2K |
| Earning Date | 01-01-0001 | 06-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.14 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $57,840,000.00 | $509,589.00 |
| Revenue This Year | N/A | $735.18 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.07 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.06 | $0.61 |
| 52 Week High | $5.64 | $4.02 |
| Indicator | APT | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 32.84 |
| Support Level | $4.44 | $1.15 |
| Resistance Level | $5.19 | $1.52 |
| Average True Range (ATR) | 0.21 | 0.11 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 62.69 | 32.36 |
Alpha Pro Tech Ltd is in the business of protecting people, products and environments. It is developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets. It also manufacture a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply: consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment and synthetic roof underlayment accessories.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.